129 Results for "

tumor progression

" in MedChemExpress (MCE) Product Catalog:
Products (129)

129 Results for "tumor progression" in MCE Product Catalog:

20
20 Publications Verification
Cat. No.: HY-W854659
CAS No.: 72984-36-2
Synonyms: Ce6 trisodium
Chlorin e6 Ce6 (trisodium) is a water-soluble derivative of chlorophyll, belonging to the chlorin class of photosensitizers with an absorption wavelength range of 600-670 nm. Chlorin e6 trisodium emits characteristic red fluorescence upon light excitation, enabling real-time identification of tumor boundaries and progression. Chlorin e6 trisodium can be used for the study of photodynamic therapy (PDT) of cancers (bladder cancer) and fluorescence diagnosis of neoplastic lesions .
loading...
    loading...
8
8 Cited Publications
Cat. No.: HY-19322
CAS No.: 1210608-43-7
Synonyms: LGH447
Target:  

Pim Apoptosis

Research Areas:  

Cancer

PIM447 (LGH447) is a potent, orally available, and selective pan-PIM kinase inhibitor, with Ki values of 6, 18, and 9 pM for PIM1, PIM2, and PIM3, respectively. PIM447 displays dual antimyeloma and bone-protective effects. PIM447 induces apoptosis .
loading...
    loading...
6
6 Cited Publications
Cat. No.: HY-135899
CAS No.: 1807758-81-1
Purity:  98.81%
Target:  

Sirtuin Apoptosis

Research Areas:  

Cancer

SIRT7 inhibitor 97491, a potent SIRT7 inhibitor with an IC50 of 325 nM, reduces deacetylase activity of SIRT7 in a dose-dependent manner. SIRT7 inhibitor 97491 prevents tumor progression by increasing p53 stability through acetylation at K373/382. SIRT7 inhibitor 97491 promotes apoptosis through caspase pathway. .
loading...
    loading...
5
5 Cited Publications
Cat. No.: HY-N9933
CAS No.: 25696-60-0
Synonyms: TβMCA
Tauro-β-muricholic acid (TβMCA) is an orally active trihydroxylated bile acid and a competitive, reversible FXR antagonist (IC50=40 μM). Tauro-β-muricholic acid inhibits bile acid-induced hepatocyte apoptosis by maintaining mitochondrial membrane potential, while simultaneously inhibiting intestinal FXR signaling, affecting bile acid synthesis, hepatic lipid metabolism, and insulin sensitivity. Accumulation of tauro-β-muricholic acid disrupts metabolic homeostasis, promoting cancer stem cell proliferation and tumor progression. The mechanisms of tauro-β-muricholic acid involve two aspects: first, inhibiting the translocation of the pro-apoptotic protein Bax to mitochondria and maintaining mitochondrial membrane potential (MMP); and second, blocking the FXR signaling pathway to regulate bile acid metabolism, reduce serum ceramide production, and downregulate the hepatic SREBP1C/CIDEA pathway. Tauro-β-muricholic acid possesses anti-hepatocyte apoptosis, bile acid homeostasis regulation, and liver fat accumulation reduction properties, and also functions as a biomarker, making it useful in the study of diseases such as bile acid metabolism disorders, non-alcoholic fatty liver disease, colorectal cancer, and liver fibrosis .
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-P1408
CAS No.: 404882-00-4
Target:  

Integrin VEGFR

Research Areas:  

Cancer

Obtustatin is a non-RGD disintegrin consisting of 41 residues. Obtustatin inhibits the adhesion of α1β1 integrin to type IV Collagen (HY-NP003), blocks α1β1 integrin signaling in endothelial cells, and suppresses FGF2-induced angiogenesis. Obtustatin inhibits tumor progression in mouse models and upregulates VEGF expression in sarcoma-bearing mice. Obtustatin can be used in research related to Lewis lung carcinoma and S-180 sarcoma .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-19542
CAS No.: 124753-97-5
Synonyms: C6-Cer; N-Hexanoylsphingosine
Target:  

Apoptosis

Research Areas:  

Cancer

C6 Ceramide (C6-Cer) is a short-chain, cell-permeable ceramide pathway activator with anticancer activity. C6 Ceramide-mediated miR-29b expression participates in the progression of multiple myeloma through suppressing the proliferation, migration and angiogenesis of endothelial cells by targeting Akt signal pathway. C6 Ceramide exhibits multiple anti-cancer properties including cell cycle arrest, Apoptosis, inhibition of tumor growth and enhances the effects of chemotherapy in drug-resistant cancer cells. C6-ceramide can be used as an adjuvant for chemotherapeutic agents, to enhance anti-tumor effects .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-100789
CAS No.: 1312471-39-8
Purity:  99.90%
Research Areas:  

Cancer

ON1231320 is a highly specific polo like kinase 2 (PLK2) inhibitor with an IC50 of 0.31 μM. ON1231320 blocks tumor cell cycle progression in the G2/M phase in mitosis, causing apoptotic cell death. ON1231320, an arylsulfonyl pyrido-pyrimidinone, has antitumor activity .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-W369099
CAS No.: 1420290-88-5
Target:  

STAT Apoptosis

Research Areas:  

Cancer

HJC0152 (free base) is an orally active and potent inhibitor of STAT3. HJC0152 (free base) inhibits cell cycle progression and induces apoptosis. HJC0152 (free base) significantly suppresses MDA-MB-231 xenograft tumor growth in mice .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-B0327
CAS No.: 57381-26-7
Synonyms: Dicloguamine
Irsogladine (Dicloguamine) is an orally active gastric mucosal protective agent. Irsogladine inhibits breast cancer recurrence and lung metastasis in nude mice . Irsogladine inhibits the transcriptional activities of NF-κB and AP-1, suppresses the activities of PDE and PDE4 to elevate intracellular cAMP levels, and activates TRPV1 and KATP channels. Irsogladine enhances iNOS expression, NO production, and the activation of cAMP-responsive elements. Irsogladine inhibits the development and progression of intestinal polyps in Apc-mutant mice. Irsogladine alleviates oxidative stress, increases gastric mucosal blood flow, and stimulates the production of endogenous prostaglandins. Irsogladine promotes insulin secretion in MIN6 cells. Irsogladine inhibits tumor angiogenesis, cancer cell proliferation, and the production of proinflammatory cytokines. Irsogladine exerts protective effects on astrocytes in ethanol/hydrochloric acid-induced gastric ulcers in mice. Irsogladine prevents colitis in IL-10 gene-deficient mice by reducing the production of IL-12 and IL-23. Irsogladine upregulates gap junction intercellular communication in pancreatic cancer cells via the PKA pathway. Irsogladine is applicable to research related to breast cancer, intestinal polyposis, gastric ulcer, spontaneous colitis, glioma, liver cancer, and pancreatic cancer [5][6] .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-133558
CAS No.: 2305757-96-2
Purity:  99.63%
Research Areas:  

Cancer

VII-31 is a potent NEDDylation pathway activator to inhibit the tumor progression in vitro and in vivo. VII-31 induces apoptosis via intrinsic and extrinsic pathways .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-32015
CAS No.: 915365-57-0
Target:  

MAP3K

Research Areas:  

Inflammation/Immunology

Cot inhibitor-1 (compound 28) is a selective tumor progression loci-2 (Tpl2) kinase inhibitor with an IC50 of 28 nM. Cot inhibitor-1 shows an inhibition of TNF-alpha production in human whole blood with an IC50 of 5.7 nM .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-149482
CAS No.: 3084190-39-3
Purity:  99.05%
Target:  

Cathepsin

Research Areas:  

Cancer

LN5P45 is an OTUB2 inhibitor (IC50: 2.3 μM). LN5P45 induces monoubiquitination of OTUB2 on lysine 31. LN5P45 can be used for research of tumor progression and metastasis .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-W854385A
Synonyms: SLeA sodium
Research Areas:  

Cancer

Sialyl Lewis A (SLeA) sodium is a tumor-associated carbohydrate antigen, also known as carbohydrate antigen 19-9 (CA19-9), that binds to E-selectin (ELAM-1) and selectins to mediate cell-endothelium adhesion. Sialyl Lewis A sodium promotes cancer cell-vascular endothelium adhesion, and its surface presence correlates with increased tumorigenicity and invasiveness in cancer cells. Sialyl Lewis A sodium shows elevated expression in human adenocarcinomas of the colon, pancreas, and stomach, with expression levels linked to tumor progression and poor prognosis in colorectal and gastric carcinomas. Sialyl Lewis A sodium can be used for the research of cancers, such as colon, pancreas, stomach, and squamous lung cancer .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-130257
CAS No.: 2509359-75-3
Purity:  99.31%
Target:  

PROTACs APC Apoptosis

Research Areas:  

Cardiovascular Disease Cancer

CP5V is a Cdc20 PROTAC degrader with a DC50 of 1.6 μM and a Kd value of 12.4 μM. CP5V couples Cdc20 with the VHL/VBC complex, triggering its ubiquitination and proteasomal degradation, thereby reducing the protein levels of Cdc20 and securin. CP5V induces mitotic arrest, inhibits cell proliferation, resensitizes Paclitaxel-resistant breast cancer cells, and suppresses breast tumor progression in xenograft models. CP5V inhibits excessive proliferation and induces apoptosis in pulmonary arterial hypertension smooth muscle cells and fibroblasts. CP5V can be used in studies related to breast cancer and pulmonary arterial hypertension .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-N3415
CAS No.: 3301-49-3
Kumatakenin is an orally active apoptosis inducer and autophagy inhibitor, with a Kd value of 2.94 μM for mouse ATG5. Kumatakenin increases the activities of caspase-3, caspase-8 and caspase-9, thereby inducing caspase-dependent apoptosis in ovarian cancer cells. Kumatakenin reduces the expression of chemokines and pro-oncogenic factors in ovarian cancer cells, and inhibits M2 macrophage polarization. Kumatakenin inactivates TRIM65 function, reduces the expression and stability of FASN, and thus inhibits the proliferation, migration, invasion and tumor progression of esophageal cancer cells. Kumatakenin interacts with ATG5 to reduce its protein level, decrease LC3 level, and reduce the number of autophagosomes in the hippocampus. Kumatakenin binds to Eno3 to upregulate its expression, reduce the stability and expression level of IRP1 mRNA, inhibit ferroptosis, alleviate intestinal inflammation, and restore epithelial barrier function. Kumatakenin enhances the efficacy of antibiotics against pathogenic bacteria, inhibits SARS-CoV-2 replication, and reduces cytokine production. Kumatakenin is applicable to research related to ovarian cancer, esophageal cancer, depression and colitis .
loading...
    loading...
Cat. No.: HY-119711
CAS No.: 161314-17-6
Purity:  99.6%
Target:  

MMP

Research Areas:  

Cancer

NNGH is a stromelysin-1 (MMP-3) inhibitor. MMP-3 is both a direct transcriptional target and a necessary contributor of the Wnt/β-catenin signaling pathway. Matrix metalloproteinases (MMPs) play a well-defined role in later stages of tumor progression .
loading...
    loading...
Cat. No.: HY-W013272
CAS No.: 52806-53-8
Synonyms: HFT
Hydroxyflutamide (HFT) is the active metabolite of Flutamide (HY-B0022) and exhibits oral activity. Hydroxyflutamide is a potent androgen receptor antagonist with an IC50 of 700 nM. Hydroxyflutamide can affect embryonic development and reproductive tract development in mice. Additionally, Hydroxyflutamide can enhance the efficacy of Bacillus Calmette-Guérin (BCG) to better inhibit the progression of bladder cancer. Hydroxyflutamide can be used in research related to tumors and reproductive diseases .
loading...
    loading...
Cat. No.: HY-P991319

Target:  

Inhibitory Antibodies

Research Areas:  

Cancer

TAB-004 is a murine IgG1 monoclonal antibody that specifically binds to the tumor-associated hypoglycosylated mucin 1 (tMUC1), with high selectivity for human tMUC1. TAB-004 can be conjugated with Indocyanine green (ICG) (HY-D0711) for in vivo targeted imaging. TAB-004 can be used for the research of early detection, tumor progression monitoring and cancer stem cell targeting in breast cancer and pancreatic cancer.
loading...
    loading...
Cat. No.: HY-141831
CAS No.: 2298390-71-1
Research Areas:  

Cancer

STF-1084 is a specific, cell-impermeable, competitive inhibitor of ENPP1 (Ki = 33 nM). STF-1084 increases extracellular cGAMP concentrations by preventing its degradation by ENPP1, thereby enhancing immune infiltration. STF-1084 acts synergistically with ionizing radiation (IR) and cGAMP to delay tumor progression. STF-1084 can be used to study cancers with low immunogenicity .
loading...
    loading...
Cat. No.: HY-145601
CAS No.: 2230490-29-4
Purity:  98.45%
Synonyms: TT 00420
Target:  

Aurora Kinase FGFR VEGFR

Research Areas:  

Cancer

Tinengotinib (TT00420) is an orally active, spectrally selective small molecule kinase inhibitor targeting Aurora A/B (IC50=1.2-3.3 nM), FGFR1/2/3 (IC50=1.5-3.5 nM), VEGFRs, JAK1/2 and CSF1R. Tinengotinib blocks Aurora kinase-mediated cell cycle progression (inducing G2/M arrest), inhibits FGFR/JNK-JUN signaling pathway and activates MEK/ERK-dependent apoptotic pathway. Tinengotinib has the activity of anti-tumor proliferation, inducing apoptosis, inhibiting angiogenesis and regulating tumor microenvironment. Tinengotinib can be used in the study of triple-negative breast cancer (TNBC), gallbladder cancer and tumor immune microenvironment .
loading...
    loading...